Tonix Pharmaceuticals has appointed Dr Donald Kellerman to head the strategy and execution of its clinical programmes.
Dr Kellerman brings 30 years of industry experience to his new role as senior VP, clinical development and regulatory affairs.
This includes his most recent role as VP, scientific affairs for Allergan’s inhalation products business. He took on this role after his previous company, Map Pharmaceuticals, was taken over by Allergan in 2013.
At Map, Dr Kellerman served as senior VP, clinical development and medical affairs at Map Pharmaceuticals having joined the company in 2008 from Inspire Pharmaceuticals.
He also has experience at GlaxoWellcome as director of respiratory clinical research.